Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C) antibody

Antigen: Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C)

Synonyms: BWS, WBS, p57, BWCR, KIP2, cb961, p27Xic1-a, zgc:86618

Clonality: Monoclonal (A120-1)

Host: Mouse

Reactivity: Human

Conjugate: Un-conjugated

Application: Western Blotting (WB)

Catalog no.: ABIN967507

Additional Information

Alternative name: p57 Kip2

Immunogen: p57[Kip2] Recombinant Human

Format: Liquid

Isotype: IgG1

Clone: A120-1

Description: Cyclin dependent kinase inhibitors (CdkIs) inhibit progression through the cell cycle by binding to cyclins, Cdks, or cyclin-Cdk complexes. CdkIs are classified into two groups based on protein structure. p57[Kip2] belongs to a group that also includes p27[Kip1] and p21 (also known as Sdi1, Cip1, Waf1 and Pic1). Members of this group have a homologous amino-terminal Cdk inhibitory domain. Members of the second group [p16 (INK4A), p15 (INK4B), p18 (INK4C), and p19 (INK4D)] contain ankyrin repeat motifs. p57[Kip2] is a potent, tight-binding inhibitor of several G1 and S phase cyclin-Cdk complexes including cyclin E-Cdk2, cyclin D2-Cdk4, and cyclin A-Cdk2. It inhibits the mitotic cyclin B1-Cdk1 complex to a lesser extent. mRNA studies suggest that p57[Kip2] expression is tissue-specific, the highest levels have been found in embryonic and adult skeletal muscle, heart, kidney, lung, eye and brain. This is in contrast to the widespread tissue expression of p27[Kip1] and p21 mRNA. The expression of p57[Kip2] to primarily terminally differentiated cells suggests that p57[Kip2] may play a specialized role in cell cycle control. Clone A120-1 reacts with human p57[Kip2]. Recombinant human p57[Kip2] was used as immunogen.

Characteristics: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Molecular Weight: 57 kDa

Comments:

Related Products: ABIN967389

Application Details

Application Notes: Applications for clone A120-1 include western blot analysis (1-2 µg/ml). SJCRH30 human rhabdomyosarcoma cells are suggested as a positive control (ATCC CRL-2061).

Concentration: 0.5 mg/ml

Purity: Purified

Purification: Purified from tissue culture supernatant or ascites by affinity chromatography.

Buffer: Aqueous buffered solution.

Preservative: 0.09% Sodium azide.

Storage: Store undiluted at 4°C.

Research Area: Cancer, Cell Cycle

Restrictions: For Research Use only

Images

Western blot analysis of p57[Kip2]. Lane 1, SJCRH30 human rhabdomyosarcoma cell lysate was probed with anti-p57[Kip2]. In lane 2, mouse IgG1 isotype (negative) control. p57[Kip2] is identified as an ~57 kDa doublet.

anti-Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C) antibody (Image 2)

Publications

Product: Graña, Reddy: "Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)." in: Oncogene, Vol. 11, Issue 2, pp. 211-9, 1995 (PubMed).

Lee, Reynisdóttir, Massagué: "Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution." in: Genes & development, Vol. 9, Issue 6, pp. 639-49, 1995 (PubMed).

Matsuoka, Edwards, Bai et al.: "p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene." in: Genes & development, Vol. 9, Issue 6, pp. 650-62, 1995 (PubMed).